DOYLESTOWN, PA--(Marketwire - October 25, 2007) - QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Follicle Stimulating Hormone (FSH) lateral flow immunoassay test for the detection of FSH at 10ng/ml. The QuantRx Biomedical Female Fertility test is a one-step lateral flow device that determines ovarian reserve indirectly by measuring FSH in first morning urine. The product is intended to aid women who are attempting to conceive and are experiencing difficulty. The QuantRx Biomedical Female Fertility test can produce results within 15 minutes, approximately half the time of the sole competing product currently in the marketplace.
